COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,196 Articles (22,713 medRxiv, 8,483 bioRxiv)

Most recent first Previous |  Page 81: Articles 801-810  | Next

Ketamine inhibition of SARS-CoV-2 replication in astrocytes is associated with COVID-19 disease severity in a variant-dependent manner
Furlani, B., Potokar, M., Korva, M., Resman Rus, K., Pozvek, P., Zorec, T. M., Vrsnik, J., Pirnat, S., Tavcar Verdev, P., Smolic, T., Horvat, A., Radinovic, K., Graselli Kmet, N., Avsic-Zupanc, T., Vardjan, N., Stenovec, M., Jereb, M., Jorgacevski, J., Zorec, R.
10.1101/2025.03.29.646083 — Posted: 2025-04-01
Modeling viral and bacterial infections in human lung organotypic systems reveals strain specific host responses
Faria Fonseca, B., Wong-Ng, J., Connor, M., Mary, H., Kim, M. H., Yim, R., BONDET, V., Michel, V., Strick Marchand, H., Di Santo, J. P., Duffy, D., Hamon, M. A., Sauvonnet, N., Chakrabarti, L. A., Gobaa, S.
10.1101/2025.03.31.644992 — Posted: 2025-04-01
A NanoBRET-based assay monitoring interactions in the USP18 signaling hub identifies the first cell-penetrant small molecule compromising USP18/ISG15 binding
Hess, S., Campos-Alonso, M., Brand, M., Lauw, S., Lindenmann, U., Goebel, K., Geurink, P. P., Fritz, G., Riedl, R., Knobeloch, K.-P.
10.1101/2025.03.30.646166 — Posted: 2025-04-01
Divalent cations govern the activity of coronavirus nsp15
Wang, X., Li, J., Liu, Z., Wang, L., Zhu, B.
10.1101/2025.03.29.646087 — Posted: 2025-03-31
Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity
Marden, G. C., Schmitt, K. P., Zimmerman, M. I., Ramos, A. H., Menzenski, M. Z., Sharma, G., Li, H., Carlin, E., Jecrois, A., Morales-Perez, C. L., Palovcak, E., Garlick, J. D., Hannigan, B., Russell, P., Federman, R. S., Leung, A., Vargas, N. L., Shaban, N. M., Vaidya, V., Towler, H., Joh, N. H., Lord, D. M., Tao, J., Costello, Z., Frappier, V., Hopson, K., Pegu, A., Koh, G. C. K. W., Van Epps, H., Root, A., Grigoryan, G., Hazuda, D., Borriello, F.
10.1101/2025.03.30.646023 — Posted: 2025-03-31
The CCR2 inflammatory pathway is a target for improving severe disease and pulmonary inflammation in experimental COVID-19
Kazungu, Y., Hegde, S., Sharma, P., Marriott, A., Steven, A., Reine, J., Dagley, J. L., Mack, M., Stewart, J. P., Turner, J. D.
10.1101/2025.03.28.645941 — Posted: 2025-03-31
Gut barrier integrity biomarkers are associated with increased inflammation and predict disease status in hospitalized COVID-19 patients
Basting, C. M., Schroeder, T., Ferbas, K., Shields-Cutler, R., Tobin, N., Velez, A., Swanson, E., Broedlow, C. A., Langat, R., Schifanella, L., Bramante, C. T., Aldrovandi, G. M., Rimoin, A., Yang, O. O., Fulcher, J. A., Klatt, N. R.
10.1101/2025.03.28.645914 — Posted: 2025-03-31
Immuno-functionomics reveals geographical variation and a role for TLR8 in mRNA vaccine responses
Huisman, W., Azimi, S., Nguyen, Y. N., de Kroon, A. C., de Ruiter, K., Tahapary, D. L., Manurung, M. D., Pothast, C. R., Kruize, Y. C. M., Heemskerk, M. H. M., Supali, T., Visser, L. G., Roukens, A. H. E., Yazdanbakhsh, M., Jochems, S. P.
10.1101/2025.03.28.645987 — Posted: 2025-03-31
Biophysical fitness landscape design traps viral evolution
Mohanty, V., Shakhnovich, E. I.
10.1101/2025.03.30.646233 — Posted: 2025-03-31
Performance characteristics of the SARS-CoV-2 Isothermal Molecular Assay for point-of-care molecular diagnosis of SARS-CoV-2
Onwuamah, C. K., Shaibu, J. O., Amoo, S. O., Ahmed, A.-R. A., Abimbola, B. S., Audu, R. A., Salako, B. L.
10.1101/2025.03.29.25324880 — Posted: 2025-03-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).